Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up A total of 962 cases of CML on ...
Human chronic myelogenous leukemia (CML) and a subset of acute lymphocytic leukemia (ALL) are caused by expression of Bcr-Abl, a fusion gene generated by reciprocal t(9;22)(q34;q11) chromosome ...
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...
Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial This is ...
Increased understanding of the precise molecular mechanisms involved in cell survival and cell death signaling pathways offers the promise of harnessing these molecules to eliminate cancer cells ...
Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered to ...
NEW HAVEN, Conn., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its new quantitative BCR-ABL 2.0 panel, with features ...
Junya Kuroda, Hamsa Puthalakath, Mark S. Cragg, Priscilla N. Kelly, Philippe Bouillet, David C. S. Huang, Shinya Kimura, Oliver G. Ottmann, Brian J. Druker, Andreas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results